Lite Strategy, Inc. Common Stock (LITS) Stock Price

LITSStock

$1.15−37.84%52W

Market Cap$34.97M

P/E—

PEG Ratio2.22

Div yield—

Beta0.07

LITS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.91%

Price vs S&P 500 (4W)-8.83%

PEG Ratio2.22

VGM Score66.21

Book Value / Share (Quarterly)$1.28

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.28

Price vs S&P 500 (YTD)-24.81%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)39.05%

EPS (TTM)$-1.74

10-Day Avg Trading Volume0.45M

EPS Excl Extra (TTM)$-1.74

EPS (Annual)$-2.39

Dividend / Share (Annual)$0.00

ROI (Annual)-94.18%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-92.08%

Cash / Share (Quarterly)$0.18

ROA (Last FY)-87.20%

EBITD / Share (TTM)$-1.96

ROE (5Y Avg)-71.43%

Operating Margin (TTM)34.86%

Cash Flow / Share (Annual)$-0.28

P/B Ratio0.84x

P/B Ratio (Quarterly)0.75x

Net Income / Employee (Annual)$-3,986,300

Net Interest Coverage (TTM)-21.51x

ROA (TTM)-67.48%

EPS Incl Extra (Annual)$-2.39

Current Ratio (Annual)5.74x

Quick Ratio (Quarterly)5.34x

3-Month Avg Trading Volume0.43M

52-Week Price Return-37.84%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)0.54x

Asset Turnover (Annual)1.58x

52-Week High$2.26

Operating Margin (5Y Avg)-100.94%

EPS Excl Extra (Annual)$-2.39

26-Week Price Return0.00%

Quick Ratio (Annual)5.34x

13-Week Price Return16.56%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.74x

Enterprise Value$29.26M

Asset Turnover (TTM)0.84x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)27.23%

Cash / Share (Annual)$0.18

3-Month Return Std Dev78.09%

Gross Margin (5Y Avg)38.18%

Net Income / Employee (TTM)$-9,924,800

ROE (Last FY)-94.18%

EPS Basic Excl Extra (Annual)$-2.39

P/FCF (TTM)0.48x

Receivables Turnover (TTM)1306.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.74

Receivables Turnover (Annual)1305.94x

ROI (TTM)-68.86%

P/S Ratio (TTM)0.33x

Pretax Margin (5Y Avg)-92.08%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)-53.37%

Year-to-Date Return-12.88%

5-Day Price Return-5.74%

EPS Normalized (Annual)$-2.39

ROA (5Y Avg)-24.99%

Net Profit Margin (Annual)27.23%

Month-to-Date Return-12.88%

EBITD / Share (Annual)$-2.56

Operating Margin (Annual)22.27%

ROI (5Y Avg)-71.43%

EPS Basic Excl Extra (TTM)$-1.74

Payout Ratio (Annual)65.59%

P/B Ratio (Annual)0.75x

Dividend / Share (TTM)$0.00

Pretax Margin (TTM)39.05%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)13.88%

Dividend Yield (TTM)0.00%

Beta0.07x

P/FCF (Annual)1.05x

Revenue / Share (TTM)$0.00

ROE (TTM)-68.86%

52-Week Low$0.69

vGradeB

mGradeB

vgmGradeB

LITS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2024	Sep 19, 2024	-$1.40	-$1.13	+19.56%(+$0.27)
Q1 2024	May 9, 2024	-$1.26	-$1.37	-8.73%(-$0.11)
Q4 2023	Feb 13, 2024	-$1.27	-$1.66	-30.71%(-$0.39)
Q3 2023	Nov 9, 2023	-$1.79	$8.46	+571.31%(+$10.26)

LITS Analyst Recommendations

Aug 2025

Sep 2025

Oct 2025

Nov 2025

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LITSLite Strategy, Inc. Common Stock	B	—	B	0.3x	—	100.0%	—	$1.15
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Lite Strategy, Inc. Common Stock

Lite Strategy Inc is a clinical-stage pharmaceutical company developing novel therapies for cancer. The company's pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral PI3K inhibitor, both designed to improve patient outcomes in oncology.